Apex Biotechnology Corp.

TWSE:1733 Stock Report

Market Cap: NT$3.1b

Apex Biotechnology Balance Sheet Health

Financial Health criteria checks 6/6

Apex Biotechnology has a total shareholder equity of NT$1.8B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$2.3B and NT$557.6M respectively. Apex Biotechnology's EBIT is NT$119.0M making its interest coverage ratio -306. It has cash and short-term investments of NT$466.8M.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio-306x
CashNT$466.79m
EquityNT$1.78b
Total liabilitiesNT$557.62m
Total assetsNT$2.34b

Recent financial health updates

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Recent updates

Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Nov 21
Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Aug 06
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Mar 21
Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Apr 17
Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Mar 10
Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

Feb 17
Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Jan 27
A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

Jan 06
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Nov 22
Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Financial Position Analysis

Short Term Liabilities: 1733's short term assets (NT$1.6B) exceed its short term liabilities (NT$439.6M).

Long Term Liabilities: 1733's short term assets (NT$1.6B) exceed its long term liabilities (NT$118.0M).

Debt to Equity History and Analysis

Debt Level: 1733 is debt free.

Reducing Debt: 1733 has no debt compared to 5 years ago when its debt to equity ratio was 25.5%.

Debt Coverage: 1733 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1733 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 00:33
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apex Biotechnology Corp. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiahong LiuE.Sun Securities Investment Consulting Co. Ltd.
Ryan LiuIBTS Investment Consulting Co., Ltd.
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.